Wu L, Tsang V, Menzies AM, Sasson SC, Carlino MS, Brown DA, Clifton-Bligh R, Gunton JE. Risk factors and characteristics of checkpoint inhibitor-associated autoimmune diabetes mellitus (CIADM): a systematic review and delineation from type 1 diabetes. Diabetes Care. 2023;46:1292–9.

Article  CAS  PubMed  Google Scholar 

de Filette JMK, Pen JJ, Decoster L, Vissers T, Bravenboer B, Van der Auwera BJ, Gorus FK, Roep BO, Aspeslagh S, Neyns B, Velkeniers B, Kharagjitsingh AV. Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review. Eur J Endocrinol. 2019;181:363–74.

Article  PubMed  PubMed Central  Google Scholar 

Baden MY, Imagawa A, Abiru N, Awata T, Ikegami H, Uchigata Y, Oikawa Y, Osawa H, Kajio H, Kawasaki E, Kawabata Y, Kozawa J, Shimada A, Takahashi K, Tanaka S, Chujo D, Fukui T, Miura J, Yasuda K, Yasuda H, Kobayashi T, Hanafusa T, Consultation of the Japan Diabetes Society Committee on Type 1 Diabetes Mellitus Research. Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell deth-1 therapy. Diabetes Int. 2019;10:58–66.

Google Scholar 

Shimada A, Kawasaki E, Abiru N, Awata T, Oikawa Y, Osawa H, Kajio H, Kozawa J, Takahashi K, Chujo D, Noso S, Fukui T, Miura J, Yasuda K, Yasuda H, Imagawa A, Ikegami H. New diagnostic criteria (2023) for slowly progressive type 1 diabetes (SPIDDM): report from Committee on Type 1 Diabetes in Japan Diabetes Society (English version). Diabetol Int. 2024;15:1–4.

Article  PubMed  Google Scholar 

Kawabata Y, Ikegami H, Awata T, Imagawa A, Maruyama T, Kawasaki E, Tanaka S, Shimada A, Osawa H, Kobayashi T, Hanafusa T, Tokunaga K, Makino H, Committee on Type 1 Diabetes, Japan Diabetes Society. Differential association of HLA with three subtypes of type 1 diabetes: fulminant, slowly progressive and acute-onset. Diabetologia. 2009;52:2513–21.

Article  CAS  PubMed  Google Scholar 

Yamaguchi H, Miyoshi Y, Uehara Y, Fujii K, Nagata S, Obata Y, Kosugi M, Hazama Y, Yasuda T. Case of slowly progressive type 1 diabetes mellitus with drastically reduced insulin secretory capacity after immune checkpoint inhibitor treatment for advanced renal cell carcinoma. Diabetol Int. 2020;12:234–40.

Article  PubMed  PubMed Central  Google Scholar 

Inaba H, Morita S, Kosugi D, Asai Y, Kaido Y, Ito S, Hirobata T, Inoue G, Yamamoto Y, Jinnin M, Kimura H, Ota M, Okudaira Y, Nakatani H, Kobayashi T, Iwama S, Arima H, Matsuoka T. Amino acid polymorphisms in human histocompatibility leukocyte antigen class II and proinsulin epitope have impacts on type 1 diabetes mellitus induced by immune-checkpoint inhibitors. Front Immunol. 2023;14:1165004. https://doi.org/10.3389/fimmu.2023.1165004.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liao PF, Peng TR, Wu TW, Hu YH. Lenvatinib-associated fulminant type 1 diabetes mellitus. Am J Ther. 2023;30:e561–3.

Article  PubMed  Google Scholar 

Hansen E, Sahasrabudhe D, Sievert L. A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother. 2016;65:765–7.

Article  PubMed  PubMed Central  Google Scholar 

Matsumura K, Nagasawa K, Oshima Y, Kikuno S, Hayashi K, Nishimura A, Okubo M, Uruga H, Kishi K, Kobayashi T, Mori Y. Aggravation of diabetes, and incompletely deficient insulin secretion in a case with type 1 diabetes-resistant human leukocyte antigen DRB1*15:02 treated with nivolumab. J Diabetes Investig. 2018;9:438–41.

Article  CAS  PubMed  Google Scholar 

Sakai G, Saito D, Nakajima R, Hatano M, Noguchi Y, Kurihara S, Katayama S, Inoue I, Noda M, Shimada A. Intrinsic insulin secretion capacity might be preserved by discontinuing anti-programmed cell death protein 1 antibody treatment in ‘anti-programmed cell death protein 1 antibody-induced’ fulminant type 1 diabetes. J Diabetes Investig. 2018;9:448–9.

Article  PubMed  PubMed Central  Google Scholar 

Nishimura A, Matsumura K, Kikuno S, Nagasawa K, Okubo M, Mori Y, Kobayashi T. Slowly progressive type 1 diabetes mellitus: current knowledge and future perspectives. Diabetes Metab Syndr Obes. 2019;12:2461–77.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suyama K, Iwase H. Lenvatinib: a promising molecular targeted agent for multiple cancers. Cancer Control. 2018;25:1073274818789361.

Article  PubMed  PubMed Central  Google Scholar 

Fountas A, Diamantopoulos LN, Tsatsoulis A. Tyrosine kinase inhibitors and diabetes: a novel treatment paradigm? Trends Endocrinol Metab. 2015;26:643–56.

Article  CAS  PubMed  Google Scholar 

Althubiti M. Tyrosine kinase targeting: a potential therapeutic strategy for diabetes. Saudi J Med Med Sci. 2022;10:183–91.

Article  PubMed  PubMed Central  Google Scholar 

Ak S, Patel SS, Patel S, Parikh P. Future treatment of diabetes - tyrosine kinase inhibitors. J Diabetes Metab Disord. 2022;22:61–71.

Article  Google Scholar 

Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci USA. 2008;105:18895–900.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Templeton A, Brändle M, Cerny T, Gillessen S. Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol. 2008;19:824–5.

Article  CAS  PubMed  Google Scholar 

Huda MS, Amiel SA, Ross P, Aylwin SJ. Tyrosine kinase inhibitor sunitinib allows insulin independence in long-standing type 1 diabetes. Diabetes Care. 2014;37:e87–8.

Article  CAS  PubMed  Google Scholar 

Salaroli A, Loglisci G, Serrao A, Alimena G, Breccia M. Fasting glucose level reduction induced by imatinib in chronic myeloproliferative disease with TEL-PDGFRβ rearrangement and type 1 diabetes. Ann Hematol. 2012;91:1823–4.

Article  PubMed  Google Scholar 

Gitelman SE, Bundy BN, Ferrannini E, Lim N, Blanchfield JL, DiMeglio LA, Felner EI, Gaglia JL, Gottlieb PA, Long SA, Mari A, Mirmira RG, Raskin P, Sanda S, Tsalikian E, Wentworth JM, Willi SM, Krischer JP, Bluestone JA, Greevec Trial Study Group. Imatinib therapy for patients with recent-onset type 1 diabetes: a multicentre, randomized, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2021;9:502–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Awata T, Shimada A, Maruyama T, Oikawa Y, Yasukawa N, Kurihara S, Miyashita Y, Hatano M, Ikegami Y, Matsuda M, Niwa M, Kazama Y, Tanaka S, Kobayashi T. Possible long-term efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, for slowly progressive type 1 diabetes (SPIDDM) in the stage of non-insulin-dependency: an open-label randomized controlled pilot trial (SPAN-S). Diabetes Ther. 2017;8:1123–34.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wang X, Zheng P, Huang G, Yang L, Zhou Z. Dipeptidyl peptidase-4 inhibitors: promising new agents for autoimmune diabetes. Clin Exp Med. 2018;18:473–80.

Article  PubMed  Google Scholar 

Gurgel Penaforte-Saboia J, Cour CEB, Vasconcelos Albuquerque N, Lauanna Lima Silva V, da Cunha Bitar, Olegario N, Oliveira Fernandes V, Montenegro Junior RM. Emerging roles of dipeptidyl peptidase-4 inhibitors in delaying the progression of type 1 diabetes mellitus. Diabetes Metab Syndr Obes. 2021;14:565–73.

Article  PubMed  PubMed Central  Google Scholar 

Hirata T, Shimada A, Morimoto J, Maruyama T. Slowly progressive type 1 diabetes treated with metformin for five years after onset. Intern Med. 2013;52:2635–7.

Article  PubMed  Google Scholar 

The Diabetes Control and Complication Trial Research Group. Effect of intensive therapy on residual β-cell function in patients with type 1 diabetes in the diabetes control and complication trial. Ann Intern Med. 1998;128:517–23.

Article  Google Scholar